title: Plasma 15-F2t isoprostane concentrations are increased during acute fructose loading in type 2 diabetes.
abstract: OBJECTIVE
  Fructose consumption is increasing worldwide and is likely to play a role in metabolic disorders. Dietary fructose is often recommended for diabetic patients, as this form of carbohydrate leads to a lower postprandial rise in plasma glucose and insulin. However, fructose contributes to the generation of free radicals. The aim of this work was to investigate the acute effects of a fructose load in patients with type 2 diabetes mellitus (T2DM), compared with healthy controls, on several metabolic oxidative biomarkers, particularly plasma 15-F2t isoprostanes (15-F2t isoPs).
  
  
  METHODS
  Six T2DM patients and six healthy subjects were recruited. All patients underwent a single fructose tolerance test (75 g of anhydrous fructose). Plasma 15-F2t isoPs concentrations, plasma total antioxidant capacity (TAS) and thiobarbituric acid reactive substances (TBARS) were measured at baseline, and at 60, 120, 180 and 240 min after fructose absorption.
  
  
  RESULTS
  Baseline plasma 15-F2t isoPs concentrations were significantly increased in T2DM patients compared with controls (310+/-47 versus 237+/-20 pg/mL, respectively; P<0.01) and rose significantly (P<0.01) to 414+/-45 pg/mL in diabetic patients. No change in TAS or TBARS was observed in either group.
  
  
  CONCLUSIONS
  Plasma 15-F2t isoPs are increased during acute fructose loading in T2DM. Knowing the potentially deleterious effect of plasma 15-F2t isoPs-in particular, vascular lesions-and in light of our results, it is necessary to reconsider fructose consumption in T2DM patients, as we can now show, for the first time, a possible association between acute fructose loading and deleterious effects in such patients.
authors.affiliation: Inserm, ERI17, laboratoire d'étude de la physiopatologie de l'hypoxie (HP2), département de biologie intégrée, hôpital Albert-Michallon, CHU de Grenoble, 38042 Grenoble, France. pfaure@chu-grenoble.fr <pfaure@chu-grenoble.fr>
authors.forename: P
authors.initials: P
authors.lastname: Faure
authors.forename: C
authors.initials: C
authors.lastname: Polge
authors.forename: D
authors.initials: D
authors.lastname: Monneret
authors.forename: A
authors.initials: A
authors.lastname: Favier
authors.forename: S
authors.initials: S
authors.lastname: Halimi
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000097:blood; D005215:Fasting; D005260:Female; D005632:Fructose / Q000494:pharmacology*; D006801:Humans; D007773:Lactates / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D007773:Lactates; D008074:Lipoproteins; D014280:Triglycerides; C075750:8-epi-prostaglandin F2alpha; D005632:Fructose; D002784:Cholesterol; D015237:Dinoprost